Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

Abstract: The present disclosure generally relates to binding agents that are capable of targeting tumor cells and/or immune cells and their use for treating cancer. The binding agents of the present disclosure comprise one or more antigen binding domains of single domain antibodies which are capable of binding to Cluster of Differentiation 36 (CD36), to Programmed Cell Death protein 1 (PD-1) and/or to Cluster of Differentiation 47 (CD47). The binding agents of the present disclosure are monospecific or multispecific and may be in the form of monomers or multimers.

Abstract: The present disclosure generally relates to binding agents that are capable of targeting tumor cells and immune cells. The binding agents of the present disclosure are multispecific and comprise antigen binding domains that are capable of binding to Dopamine Receptor D2 (DR2), to Programmed Cell Death Protein 1 (PD-1) and/or to Cluster of Differentiation 47 (CD47). The multispecific binding agents of the present disclosure may be used to treat subjects in need thereof.

Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

Abstract: The present invention relates to novel tri-specific binding molecules. The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

Abstract: Disclosed are a method, a device, a system, and/or manufacture of customizable and/or configurable electronic enhancement of a unique copy of a book through assignment and/or retrieval of data utilizing a book enhancement device, according to one or more embodiments. In one embodiment, a method includes selecting a page UID of a book and a button UID associated with an interaction indicator. The method stores an audio signal in association with the page UID and the button UID such that the book can be sound enhanced when the user selects the interaction indicator. The method then embeds a book GUID configured to uniquely distinguish a copy of the book against other copies, and such that the audio file and/or configuration file data can be queried and downloaded to a book enhancement device. The method can enable custom content and/or configuration to transfer with the book between book enhancement devices.

Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

Abstract: Disclosed are a method, a device, a system, and/or manufacture of electronic book enhancement. In one embodiment, a device includes a housing, a book coupler to secure a book to the housing, a page detection sensor generating a page signal usable to determine an open page of the book, a computer processor, a computer readable memory, and an audio output device. The computer readable memory stores an audio dataset including one or more page UIDs, one or more associated audio files, and an audio routine that includes computer readable instructions that when executed receive the page signal from the page detection sensor, determine a page UID for the open page, query the audio dataset for the audio file associated with the page UID, and generate an audio signal of the audio file on the audio output device to enhance a reading experience of the book based on the open page.

Abstract: The present disclosure generally relates to binding agents that are capable of targeting tumor cells and/or immune cells. The binding agents of the present disclosure comprise one or more antigen binding domains of heavy chain antibodies (HcAb) which are capable of binding to DR2, to PD-1 and/or to CD47. The binding agents of the present disclosure may be in the form of monomers or multimers and may be monospecific or multispecific.

Abstract: Disclosed are a method, a device, a system, and/or manufacture of electronic enhancement of a book for shared learning and/or interactive experience. In one embodiment a method includes designating a set of two or more enhancement units, e.g., a book GUID corresponding to a unique printed copy of a book and/or an enhancement device UID in combination with a book UID corresponding to any printed copy. The method generates a group UID and associates two or more enhancement units to form a group. The method generates an audio dataset through selecting the page UID of a page, receiving a first audio signal, storing the first audio signal, generating the audio dataset, and associating the page UID and the audio file such that the book can be sound enhanced for a user of the group. The method detects a network connection from an enhancement unit and transmits the audio dataset.

Abstract: Disclosed are a method, a device, a system, and/or manufacture of electronic book enhancement. In one embodiment, a device includes a housing, a book coupler to secure a book to the housing, a page detection sensor generating a page signal usable to determine an open page of the book, a computer processor, a computer readable memory, and an audio output device. The computer readable memory stores an audio dataset including one or more page UIDs, one or more associated audio files, and an audio routine that includes computer readable instructions that when executed receive the page signal from the page detection sensor, determine a page UID for the open page, query the audio dataset for the audio file associated with the page UID, and generate an audio signal of the audio file on the audio output device to enhance a reading experience of the book based on the open page.

Abstract: The present disclosure generally relates to transgenic animals comprising germline modifications at an immunoglobulin heavy chain (IgH) locus for expressing heavy chain antibodies (HCAbs) as well as nucleic acid constructs, cells and methods for generating same. The present disclosure also relates to binding agents comprising sequences derived from the heavy chain antibodies produced by the transgenic animals.

Abstract: The present invention relates to novel tri-specific binding molecules. The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Abstract: Various embodiments of the present technology are directed to methods for workload management and automation. In some embodiments the methods include (A) executing a workflow using a request/response API, the workflow design-time comprising: (i) defining a task and process and run-time requirements of the workflow; (ii) assembling and sequencing of the work into a workflow; (iii) defining execution affinities, dependencies, and completion criteria of the workflow; and (iv) scheduling the workflow; (B) executing a workflow run-time, the workflow run-time comprising: (i) receiving a request for the work using the request/response API; (ii) executing the workflow using the workflow design-time and the request/response API; and (iii) sending a response after the executing of the workflow using the request/response API.

Abstract: In general, the subject matter described in this specification can be embodied in methods for accessing a presentation stored on a remote server with a first computing device that is connected to the remote server over a network. The first computing device communicates with the network over a wireless connection. The first computing device is used to cause a second computing device to display the presentation. The second computing device is connected to the remote server over a network. The display of the presentation is substantially controlled with communication between the first computing device and the second computing device. The communication occurs only through the remote server.